This Under-The-Radar Cancer Biotech Reports 21% Tumor Shrinkage: Analysts See 600%+ Upside

This is sponsored content.  Barchart is not endorsing the websites or products set forth below.

A clinical-stage biotech company focused on synthetic lethality has reported promising progress across its cancer drug pipeline, highlighted by early signs of tumor reduction in multiple patients, with analysts projecting substantial upside potential for this under-the-radar opportunity.

Clinical Programs Show Encouraging Tumor Shrinkage

Aprea Therapeutics (APRE) recently reported first quarter 2025 financial results and provided updates on its two synthetic lethality programs - ATRN-119 (ATR inhibitor) and APR-1051 (WEE1 inhibitor).

In a key development, three patients in the ongoing ABOYA-119 study showed measurable tumor shrinkage (7%, 14%, and 21%) while receiving ATRN-119 at the 550mg twice daily dose level. These results are particularly promising since they were observed at a dose below what is expected to be the recommended Phase 2 dose.

"This is an encouraging sign, as these results were achieved at a dose level below the recommended Phase 2 dose," said Oren Gilad, Ph.D., President and CEO of Aprea. "As we progress to a dose level where clinical activity is emerging, our focus is shifting toward RP2D selection."

Meanwhile, the company's second clinical program, the ACESOT-1051 study of APR-1051 in advanced solid tumors, continues to advance with patients now being dosed at 100mg once daily. Once this dose level is complete, Aprea plans to evaluate 150mg dosing.

Analysts Project 600%+ Upside Potential

Wall Street analysts have issued bullish outlooks for Aprea, with price targets suggesting potential upside of over 600% from current levels around $1.50-$1.65.

Maxim Group's Jason McCarthy reiterated a Buy rating on APRE with a $10 price target, noting: "Stay the course with Aprea. APRE shares have pulled back significantly over the last several quarters mainly from challenging macro market factors, particularly for microcap biotech."

Similarly, Wedbush analyst Robert Driscoll maintained an Outperform rating with an $11 price target. Driscoll highlighted that "ATRN-119 continues to be well tolerated, with five (out of 32) patients reporting G3+ AEs, and only one SAE of anemia, indicative of a potentially differentiated early safety profile versus other ATRi."

Both analysts emphasized Aprea's differentiated approach compared to competitors. McCarthy noted the company's continuous dosing approach with ATRN-119, which appears to be showing a positive safety profile compared to competitors that have encountered toxicity issues requiring intermittent dosing.

Driscoll pointed out that "first generation ATR inhibitors displayed high incidence of anemia at intermittent dosing schedules, with additional incidence of heme toxicity (neutropenia, thrombocytopenia, neutrophil/platelet count decreased)."

Key Upcoming Catalysts

Aprea ended the first quarter with $19.3 million in cash, which management expects will provide runway into the second quarter of 2026. The company reported a quarterly net loss of $3.9 million ($0.66 per share).

Key upcoming catalysts include:

• Additional safety data for ATRN-119 expected in 2H 2025
• Recommended Phase 2 dose for ATRN-119 expected in 1H 2026
• Preliminary efficacy data for APR-1051 in 2H 2025
• Recommended Phase 2 dose for APR-1051 expected in 2026

Long-Term Commercial Outlook

Looking ahead, analysts model commercialization for ATRN-119 in advanced/metastatic cancers beginning in 2028-2029.

Wedbush projects potential revenues reaching $201 million by 2030, with Maxim also forecasting significant commercial potential starting with ovarian cancer in 2028 and breast cancer in 2030.

The company recently entered into a Material Transfer Agreement with MD Anderson Cancer Center, where researchers will explore APR-1051's potential in treating head and neck squamous cell carcinoma expressing genomic markers of replication stress.

Price Action: APRE stock was trading at approximately $1.50-$1.65, presenting what analysts view as a potential ground-floor opportunity as these clinical programs continue to advance toward key data readouts.

The above is sponsored content. Barchart was paid up to eleven thousand dollars for placement and promotion of the content on this site and other forms of public distribution covering the period of May - June 2025.  For more information please view the Barchart Disclosure Policy here.